Peter Alterman named COO of SAFE-BioPharma

Monday, August 13, 2012 03:13 PM

Peter Alterman, Ph.D., who held numerous senior information security positions within the U.S. federal government, has been named chief operating officer of SAFE-BioPharma Association, the strategic, non-profit collaboration responsible for the global SAFE-BioPharma digital identity and digital signature standard used in the life science and healthcare sectors.
 
Alterman recently retired after 33 years of government service where, most recently, he was senior advisor to the national program office of the National Strategy for Trusted Identities in Cyberspace (NSTIC), NIST. Before that he served as senior advisor to the NIH CIO for Strategic Initiatives, Assistant CIO for e-authentication at the National Institutes of Health and chair of the U.S. Federal PKI Policy Authority. His role in Internet technology started in 1989 as a member of the Federal Research Internet Coordinating Committee.
  
In addition to responsibilities for a variety of association management functions, Alterman will serve as SAFE-BioPharma’s primary liaison with the FDA and other global regulatory authorities and represent the association’s interests on global standards and policy bodies.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs